Dechra Pharmaceuticals
Dechra Pharmaceuticals is a global veterinary pharmaceuticals company that develops, manufactures, and distributes specialty drugs exclusively for veterinary professionals across 114 countries, with focus on endocrinology, anti-infectives, dental, and pain management for companion animals.
- Company typePrivate
- Founded1997
- HeadquartersNorthwich, United Kingdom
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Dechra Pharmaceuticals does
Dechra Pharmaceuticals is an international veterinary pharmaceuticals company that develops, manufactures, and distributes specialty pharmaceutical products exclusively for veterinary professionals. The company's portfolio is organized around key therapeutic areas for companion animals (dogs, cats, and horses), including endocrinology (CosACTHen®, Zygolide®), anti-infectives (Solovecin™, Emeprev™), dental care (VETRADENT®), and pain management. Recent R&D has yielded several first-in-class FDA approvals, including the only cosyntropin indicated for canine patients and the first bioequivalent generic pergolide for equine Cushing's disease, and the company is expanding into veterinary biologics following the 2024 acquisition of Invetx, a monoclonal antibody platform.
Dechra operates a B2B go-to-market model with no direct-to-consumer sales; products are sold through own sales offices in 27 markets and through a curated network of authorized distribution partners in an additional 87 countries, giving it coverage in 114 markets. The company runs seven manufacturing sites globally, supports customers through the Dechra Academy continuing education platform, and pursues a sustainability agenda that has delivered a 40% reduction in Scope 1 and 2 emissions five years ahead of its 2030 target. In June 2025 it divested its Avishield poultry vaccines business to Vaxxinova to refocus on companion animal specialty therapeutics.
In 2024 Dechra was taken private by EQT Group in a £4.5 billion transaction co-invested by Abu Dhabi Investment Authority (ADIA), and in 2026 it relocated its global headquarters from Northwich, England to Boston, Massachusetts, consolidating its North American footprint. The company reported revenue of approximately $967 million in 2023 (most recent disclosed period in source data), employs roughly 2,760 people globally, and has been actively reshaping its senior leadership team and product pipeline through targeted acquisitions (Invetx, Piedmont Animal Health, Med Pharmex) and a steady cadence of regulatory approvals.
Dechra Pharmaceuticals firmographics
Firmographics- Name
- Dechra Pharmaceuticals
- Legal name
- Dechra Pharmaceuticals Limited
- Website
- https://dechra.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Dechra Pharmaceuticals is a global veterinary pharmaceuticals company that develops, manufactures, and distributes specialty drugs exclusively for veterinary professionals across 114 countries, with focus on endocrinology, anti-infectives, dental, and pain management for companion animals.
- Ownership category
- akta.pro rank
Dechra Pharmaceuticals industry classification
Industry- Product category
- Veterinary Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Oncology & Specialty Therapeutics (HLAMAEAJ)
- akta.pro secondary industries
- Endocrinology & Metabolic Drugs (e.g., Diabetes, Thyroid) (HLAMAEAG), Antimicrobials & Anti-infectives (HLAMAEAE), Biologics & Immunotherapies (Non-vaccine) (HLAMAEAK)
Keywords
Where Dechra Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Northwich
- HQ country
- United Kingdom
- HQ region
- Europe
Offices7 records
Markets served
Dechra Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- Veterinary Pharmaceutical Products: Development, manufacturing, and sale of veterinary pharmaceuticals exclusively for veterinarians worldwide, including specialty care products for companion animals
- Product Licensing and Distribution: Licensing agreements for product distribution such as Intervacc's Strangvac equine strangles vaccine, and sale of product portfolios such as Avishield poultry vaccines
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Dechra Pharmaceuticals product offering
Product offeringCore offering
Dechra Pharmaceuticals develops, manufactures, and sells specialty veterinary pharmaceutical products exclusively for licensed veterinary professionals worldwide. Its portfolio spans endocrinology, anti-infectives, antiemetics, dental care, dermatology, and pain management for companion animals (dogs, cats) and horses, supplemented by distributed vaccines and recently acquired monoclonal antibody biologics.
Product overview
Dechra Pharmaceuticals is an international veterinary pharmaceuticals and related products business that operates as a single unified product portfolio serving veterinary professionals. The company provides high-quality pharmaceutical products exclusively for veterinarians worldwide, organized around therapeutic areas including endocrinology (CosACTHen®, Zygolide®), anti-infectives (Solovecin™), antiemetics (Emeprev™), dental care (VETRADENT®), and distributed vaccines (Strangvac). Dechra also acquired Invetx to expand into novel monoclonal antibody therapeutics for companion animals. The products are complemented by Dechra Academy for professional training and are distributed through direct sales channels in 27 markets plus distribution partners in 87 additional countries.
Differentiator
Problem solved
Functional benefit
Brands
- VETRADENT: Dental wipes for dogs
- Solovecin
- CosACTHen
- Zygolide
- Emeprev
- Avishield
Products and services
- CosACTHen (cosyntropin injection) FDA-approved cosyntropin injection for canine ACTH stimulation testing to evaluate adrenal function, the first and only cosyntropin specifically indicated for dogs. Used by veterinarians to diagnose, confirm, and monitor Cushing's Disease and Addison's Disease.
- Zygolide (pergolide tablets) FDA-approved bioequivalent generic pergolide tablets for controlling clinical signs associated with Pituitary Pars Intermedia Dysfunction (Equine Cushing's Disease) in horses. Available through veterinarians and major online pharmacies.
- Emeprev (maropitant citrate) Injectable Solution FDA-approved bioequivalent maropitant citrate injectable solution for the treatment of vomiting in dogs and cats. Preservative-free formulation that does not require refrigeration.
- Solovecin (cefovecin sodium) In-clinic injectable antibiotic (cefovecin sodium) for skin infections in dogs and cats. Provides a full course of therapy in a single injection, improving treatment compliance.
- VETRADENT Dental Wipes for Dogs Dental hygiene wipes for dogs that have been awarded the Veterinary Oral Health Council (VOHC) Seal of Acceptance for proven tartar control performance.
- Strangvac (equine strangles vaccine) Equine strangles vaccine distributed by Dechra in the UK, Spain, Portugal, Slovenia, and Finland under a distribution agreement with Intervacc. Used by equine veterinarians for prevention of strangles (Streptococcus equi).
- Invetx (novel monoclonal antibody therapeutics for pets) Biotechnology platform developing protein-based therapeutics and novel monoclonal antibody products for companion animals, acquired for up to $520 million in July 2024. Expands Dechra into veterinary biologics and specialty medicine.
- Piedmont Animal Health companion animal products Novel product development pipeline for the companion animal market acquired in 2022 to enhance Dechra's therapeutic areas. Products from the acquisition are expected to launch in 2024 and 2025.
Quantifiable outcome
- 98% of respondents agreed interactions with animals can have positive impact on human health, with 93% believing they could create stronger communities (Boston survey n=200)
- +2 more outcomes
Companies that use Dechra Pharmaceuticals
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Dechra Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Dechra Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- Pet Partnerscore$50,000 investment to expand animal therapy programs across Boston including education, evaluation, certification and insurance for volunteers and therapy animals. Strategic partnership rooted in elevating human-animal bond and pet wellbeing in communities.
- Boston Police Foundationminor$10,000 donation to support Boston Police Department's Comfort Dog Program community engagement initiatives, supporting positive interactions through Copper the comfort dog to foster trust and connection between law enforcement and communities.
- HABRIcoreHuman-Animal Bond Certified Company partnership providing veterinary professionals with education on scientifically-documented benefits of human-animal bond. Dechra colleagues and customers access certification training through NAVC's Vetfolio platform.
- NAVCcorePartnership with North American Veterinary Community for Human-Animal Bond Certification program delivery through Vetfolio online platform, making continuing education accessible for veterinarians.
- IntervacccoreDistribution agreement for Intervacc's equine strangles vaccine Strangvac extended by two years starting April 2026. Dechra launched vaccine in UK, Spain, Portugal, and Slovenia while Intervacc manages Scandinavia distribution. Dechra continues expanding distribution across European markets.
- VaxxinovacoreSale of Avishield poultry vaccines portfolio including eight products marketed in 29 countries. R&D team of 24 people in Zagreb transfers to Vaxxinova. Dechra manufactures and distributes products for two-year transitional period while technical transfer occurs. Dechra leasing Zagreb R&D facility for three years.
- Akston BiosciencesminorDechra purchased veterinary insulin programs from Akston Biosciences as part of expanding portfolio in veterinary therapeutics for companion animals.
- InvetxcoreAcquisition of Invetx, Boston-based biotech specializing in protein-based animal therapeutics and monoclonal antibody products for pets. Deal valued at up to $520 million, enabling expansion in veterinary biologics and specialty medicine.
- Piedmont Animal HealthcoreAcquisition agreement for Piedmont Animal Health specializing in novel product development for companion animal market. Products expected to launch in 2024 and 2025, enhancing Dechra's product pipeline and key therapeutic areas.
Scale indicators8 records
Recent moves2 records
Dechra Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Vetoquinol: Independent French veterinary pharmaceutical company serving companion and livestock markets with focus on specialty therapeutics. Direct peer in companion animal pharmaceuticals with comparable international distribution model.
- Phibro Animal Health: Animal health and mineral nutrition company offering pharmaceuticals and vaccines for livestock and companion animals. Comparable as a mid-cap specialty animal health player with global distribution, though more weighted to production animal markets.
- Virbac: Independent French animal health company focused on pharmaceuticals, vaccines, and diagnostics for companion and farm animals. Direct mid-sized competitor to Dechra in specialty veterinary pharmaceuticals, with similar global footprint and similar emphasis on companion animal health.
- Ceva Santé Animale: Global veterinary pharmaceutical company headquartered in France, with companion animal and livestock products. Direct competitor to Dechra, comparable in scale and product categories, especially in companion animal therapeutics.
- Norbrook Laboratories: Privately held veterinary pharmaceutical company headquartered in Northern Ireland, manufacturing companion and livestock animal health products. Closely comparable mid-sized veterinary pharma peer with similar proprietary anti-infective and parasiticide portfolio.
Broad incumbents
- Elanco Animal Health: Major publicly traded animal health company with companion animal and livestock pharmaceuticals, vaccines, and parasiticides. Competes with Dechra in specialty pharma categories but at much larger scale and broader portfolio.
- Zoetis: World's largest animal health company selling pharmaceuticals, vaccines, diagnostics, and biologics across companion and livestock species. Overlaps with Dechra across companion animal endocrinology, anti-infectives, and dermatology, but serves a vastly broader portfolio including livestock vaccines and diagnostics.
- Boehringer Ingelheim Animal Health: Animal health division of Boehringer Ingelheim, one of the largest veterinary pharma players with companion animal parasiticides, vaccines, and therapeutics. Overlaps Dechra in companion animal specialty pharmaceuticals with much greater scale and global reach.
Emerging players
- PetIQ: Animal health products and services company distributing pet medications, OTC, and veterinary wellness products through retail and veterinary channels. Indirect competitor on the companion animal channel side, particularly relevant given Dechra's pivot to deepen distribution to vet practices.
Others
- IDEXX Laboratories: Leader in veterinary diagnostics and software for companion animals. Not a direct pharma competitor but is a critical counterpart that drives practice-level economics and prescription behavior, and IDEXX's therapeutics and reference lab services partially overlap with Dechra's specialty positioning.
Market position
Strengths5 records
Weaknesses5 records
Key risks5 records
Key highlights7 records
Customer concentration
Dechra Pharmaceuticals social profiles
Digital presenceDechra Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dechra Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles15 records
Dechra Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries3 records
Dechra Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dechra Pharmaceuticals M&A and investment
M&A and investmentM&A14 records
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dechra Pharmaceuticals
What does Dechra Pharmaceuticals do?
Dechra Pharmaceuticals develops, manufactures, and sells specialty veterinary pharmaceutical products exclusively for licensed veterinary professionals worldwide. Its portfolio spans endocrinology, anti-infectives, antiemetics, dental care, dermatology, and pain management for companion animals (dogs, cats) and horses, supplemented by distributed vaccines and recently acquired monoclonal antibody biologics.
Is Dechra Pharmaceuticals a public or private company?
Dechra Pharmaceuticals is a private company. It is classified as private equity controlled and is currently operating.
When was Dechra Pharmaceuticals founded?
Dechra Pharmaceuticals was founded in 1997. It employs 501 to 1,000 people.
Where is Dechra Pharmaceuticals based?
Dechra Pharmaceuticals is headquartered in Northwich, United Kingdom, in the Europe region.
How does Dechra Pharmaceuticals make money?
Two revenue lines are on record. Veterinary Pharmaceutical Products are the primary driver. The others are product Licensing and Distribution.
Who are Dechra Pharmaceuticals's main competitors?
Direct peers on record are Vetoquinol, Phibro Animal Health, Virbac, Ceva Santé Animale and Norbrook Laboratories. Broad incumbents are Elanco Animal Health, Zoetis and Boehringer Ingelheim Animal Health. PetIQ is listed as an emerging player. IDEXX Laboratories is listed as an others.
Does Dechra Pharmaceuticals have an API?
No public API is recorded for Dechra Pharmaceuticals.
What industry is Dechra Pharmaceuticals in?
Dechra Pharmaceuticals's product category is Veterinary Pharmaceuticals. Its primary akta.pro industry code is HLAMAEAJ, Oncology & Specialty Therapeutics, with a secondary code of HLAMAEAG, Endocrinology & Metabolic Drugs (e.g., Diabetes, Thyroid). Its NAICS code is 325412 and its SIC code is 2834.